Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

Detalles Bibliográficos
Autores principales: Zabriskie, M S, Eide, C A, Yan, D, Vellore, N A, Pomicter, A D, Savage, S L, Druker, B J, Deininger, M W, O'Hare, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873472/
https://www.ncbi.nlm.nih.gov/pubmed/26582647
http://dx.doi.org/10.1038/leu.2015.318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873472/
https://www.ncbi.nlm.nih.gov/pubmed/26582647
http://dx.doi.org/10.1038/leu.2015.318

Ejemplares similares